Journals / Klimik Dergisi / 2018 / Cilt: 31 - Sayı: 3

Soft Tissue Infection After Antithyroid Drug-Associated Agranulocytosis

Antitiroid İlaçla İlişkili Agranülositoz Sonrası Gelişen Yumuşak Doku İnfeksiyonu

Pages
235–237
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

She was succesfully treated with a 3-week antibiotic therapy and partial thumb amputation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Agranulocytosis is a rare but life-threating side effect of antithyroid drugs such as methimazole and propylthiouracil.
📊
Key Findings & Data:Female gender, age >40 years and first 3 months of antithyroid drug use are shown as risk factors for development of agranulocytosis in the literature.
💡
Conclusion & Impact:She was succesfully treated with a 3-week antibiotic therapy and partial thumb amputation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Agranulocytosis is a rare but life-threating side effect of antithyroid drugs such as methimazole and propylthiouracil. Female gender, age >40 years and first 3 months of antithyroid drug use are shown as risk factors for development of agranulocytosis in the literature. We reported a case of soft tissue infection occurring in a patient who has all above mentioned risk factors and developed agranulocytosis/neutropenia associated with methimazole in an attempt to notice the frequency of antithyroid drug-associated agranulocytosis, its risk factors and complications. A 73-year-old female using methimazole due to hyperthyroidism for 2.5 months admitted with fever, neutropenia and paronychia. Patient who was not followed hematologically after starting antithyroid drug was diagnosed agranulocytosis/neutropenia. During her recovery period, an ischemic necrosis in nail bed and distal phalanx of left thumb and a cellulitis on left forearm developed. She was succesfully treated with a 3-week antibiotic therapy and partial thumb amputation.

Özet

Agranülositoz, metimazol ve propiltiourasil gibi antitiroid ilaçların,nadir ancak sonuçları hayatı tehdit edebilen bir yan etkisidir. Literatürde, ≥40 yaşında ve kadın olmak ve antitiroid ilaç tedavisinin ilk üç ayı, agranülositoz gelişimi açısından risk faktörü olarakgösterilmiştir. Bu yazıda, belirtilen bütün risk faktörleri bulunan vemetimazolle ilişkili agranülositoz/nötropeni gelişmiş bir hastadaortaya çıkan bir yumuşak doku infeksiyonu olgusu, antitiroid ilaçlailişkili agranülositoz sıklığı, risk faktörleri ve komplikasyonlarınadikkat çekmek amacıyla sunulmuştur. Hipertiroidi nedeniyle 2.5aydır metimazol kullanan 73 yaşında kadın, ateş, nötropeni ve paronişiyle başvurdu. Antitiroid ilaç başlandıktan sonra hemogramtakibi yapılmadığı öğrenilen hastaya agranülositoz/nötropeni tanısı konuldu. Hastada iyileşme döneminde sol el başparmak tırnakyatağıyla distal falanksta iskemik nekroz ve ön kolda selülit gelişti. Üç hafta antibiyotik tedavisi ve kısmi parmak ampütasyonuylabaşarılı bir şekilde tedavi edildi.

🔖

Cite This Article

KARAŞAHİN, Ö., YILMAZ, S. İ. (2022). Soft Tissue Infection After Antithyroid Drug-Associated Agranulocytosis. Klimik Dergisi, Cilt: 31 - Sayı: 3, 235–237. https://ajindex.com/articles/573525

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid. 2004; 14(6): 459-62
  2. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid druginduced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med. 1990; 150(3): 621-4
  3. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983; 98(1): 26-9
  4. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009; 19(6): 559-63
  5. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013; 98(12): 4776-83
  6. Guffy MM, Goeken NE, Burns CP. Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch Intern Med. 1984; 144(8): 1687-8
  7. Kim HK, Yoon JH, Jeon MJ, et al. Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: a multicenter study in Korea. Endocrinol Metab (Seoul). 2015; 30(4): 475-80
  8. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10): 1343-1421
  9. Tiroid Çalışma Grubu. Tiroid Hastalıkları Tanı ve Tedavi Kılavuzu 2017. Ankara: Türkiye Endokrinoloji ve Metabolizma Derneği, 2017: 61
  10. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007; 146(9): 657-65
  11. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf). 2004; 61(5): 589-94
  12. Cooper DS. Antithyroid drugs. N Engl J Med. 2005; 352(9): 905-17
  13. Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015; 4(3): 149-63
  14. Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid. 1993; 3(4): 305-9
  15. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not imp